Multimodal approach (surgery, chemotherapy, and radiotherapy) in the treatment of advanced ovarian carcinoma

Mariana Steiner, Raphael Rubinov, Riva Borovik, Yoram Cohen, Eliezer Robinson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Forty‐five patients with advanced ovarian carcinoma without prior chemotherapy were treated with cisplatin‐Adriamycin (doxorubicin) combination, 50 mg/m2 intravenously, for 11 cycles. Second‐look operation (SLO) was performed in patients without evidence of disease at the end of chemotherapy. Abdominopelvic irradiation was administered to those found to have microscopic or minimal disease (tumor < 2 cm) at SLO. Forty patients were evaluable. Chemotherapy induced complete response in 56.7% and partial response in 16.7%. In 25% of the reoperated patients, no tumor was found; 30% had microscopic disease; 25% had minimal disease; and 20% had larger tumors. Two‐year survival rate was 45%. The residual tumor left at initial operation, the histologic grade, and the response to chemotherapy influenced survival. Toxicity was moderate. There were three treatment‐related deaths (one due to sepsis, one due to cardiotoxicity, and one at SLO, respectively). Radiotherapy was poorly tolerated after chemotherapy. The median duration of follow‐up was 21.5 months. Further follow‐up is needed to study the long‐term benefits of this multimodal approach.

Original languageEnglish
Pages (from-to)2748-2752
Number of pages5
Issue number12
StatePublished - 1 Jan 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Multimodal approach (surgery, chemotherapy, and radiotherapy) in the treatment of advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this